Pharmacogenomics is the study of how genetic differences can influence the way individuals respond to certain medications. These differences can affect how quickly a medication is metabolized, how effective it is, or the likelihood of side effects.
These genetic variations are common. The FDA now includes pharmacogenomic information in the labeling of hundreds of medications, and research suggests that most people carry at least one genetic variant that could meaningfully affect how they process a commonly prescribed drug. That does not mean everyone needs testing, but it does mean that when medication response has been difficult to predict, genetics may be part of the explanation.
Pharmacogenomic testing can sometimes help guide medication selection and dosing, particularly for patients who have experienced medication side effects, difficulty finding effective treatment, unusual medication reactions, or complex medication regimens. While testing is not necessary for every patient or every prescription, it may provide useful clinical information in specific situations.
How Genes Affect Medication Response
People can respond very differently to the same medication. A prescription that works well for one patient may cause side effects, limited benefit, or unexpected reactions in another. Age, medical history, kidney and liver function, other medications, and lifestyle factors all play important roles, but genetics can also influence how the body processes certain drugs.
Specific genetic variations can affect whether someone metabolizes certain medications normally, more slowly, or more rapidly than expected. For some medications, this can influence drug levels, treatment response, and side effect risk.
For example, some pain medications, such as codeine and tramadol, must be processed by the liver enzyme CYP2D6 to work as intended. Patients who process these medications too slowly may get little pain relief, while those who process them too rapidly may have a higher risk of side effects or toxicity.
Understanding these genetic factors does not guarantee that a medication will or will not work. However, pharmacogenomic testing may provide additional information that helps physicians make more informed treatment decisions when selecting or adjusting certain medications.
Where Pharmacogenomic Testing Has the Strongest Evidence
Pharmacogenomic testing is not equally useful for all medications. It is most helpful when there is a well-established relationship between a specific gene and a specific medication, especially when clinical guidelines explain how the result should be used.
Examples include:
CYP2C19 and clopidogrel: Some patients may not adequately activate clopidogrel, an antiplatelet medication used after certain cardiovascular or neurologic events, which can reduce its effectiveness.
CYP2D6 and codeine or tramadol: Some patients may have limited pain relief or increased side effect risk depending on how they metabolize these medications.
CYP2C9, VKORC1, and warfarin: Genetic variations in these genes can significantly affect how much warfarin a patient needs to achieve safe and effective anticoagulation. The FDA includes genotype-specific dosing guidance in the warfarin label, and testing may be particularly helpful for patients who require unusually high or low doses.
TPMT or NUDT15 and thiopurine medications: Some patients may need dose adjustments or alternative medications due to increased toxicity risk.
HLA-B57:01 and abacavir: Testing for this genetic marker before prescribing abacavir, an HIV medication, is considered standard of care. Patients who carry HLA-B57:01 are at high risk for a potentially life-threatening hypersensitivity reaction and should not receive the drug.
These examples do not mean everyone needs pharmacogenomic testing. They show that testing is most valuable when it is connected to a specific medication decision and interpreted using evidence-based resources, such as guidance from the Clinical Pharmacogenetics Implementation Consortium, or CPIC, and pharmacogenomic information included in FDA medication labeling.
Pharmacogenomics and Mental Health Medications
Finding the right antidepressant or psychiatric medication can be frustrating. Some patients respond well to the first medication they try, while others experience side effects, limited improvement, or multiple medication changes before finding an effective option.
Pharmacogenomic testing in psychiatry primarily provides information about how the body metabolizes certain medications. It does not reliably predict whether a specific antidepressant will work for a specific person. This distinction is important.
Some studies suggest pharmacogenomic-guided prescribing may modestly improve medication response or reduce drug-gene mismatches in selected patients, but results have been mixed across larger real-world trials. Testing has shown more consistent value in helping avoid medications a patient is likely to metabolize poorly than in predicting which antidepressant will be most effective overall. For this reason, testing should not be presented as a shortcut to finding the “right” antidepressant.
For patients who have experienced significant side effects, unusual medication reactions, or multiple treatment failures, pharmacogenomic testing may provide useful additional information. It is most helpful as one piece of a broader clinical decision-making process that also considers diagnosis, symptoms, prior medication history, other health conditions, current medications, and patient goals.
Pharmacogenomics and Pain Management
Pain medications can vary significantly in how they affect different individuals. Some patients experience adequate relief with standard dosing, while others have limited benefit or side effects even at lower doses. In certain cases, genetic differences in drug metabolism can partly explain these variations.
The clearest examples involve medications such as codeine and tramadol, which depend in part on CYP2D6 metabolism. Patients who are poor metabolizers may not convert enough of the medication into its active form, leading to inadequate pain relief. Patients who are ultrarapid metabolizers may be at greater risk of side effects because of higher-than-expected active drug levels.
Drug interactions matter as well. A patient’s genetic result does not exist in isolation. Certain medications, including some antidepressants, can inhibit CYP2D6 and make a person function more like a poor metabolizer, even if their genetic result suggests normal metabolism. This is one reason pharmacogenomic testing must be interpreted alongside the full medication list.
Pain management remains complex and influenced by many factors beyond genetics alone, including the underlying pain condition, other medications, sleep, mental health, inflammation, and overall medical history. Pharmacogenomics is not a standalone solution for chronic pain, but in select patients, it may provide additional information that helps guide safer and more individualized medication decisions.
Important Limitations of Pharmacogenomic Testing
Pharmacogenomic testing can be valuable, but it has important limits.
Testing primarily helps assess pharmacokinetics, meaning how the body processes a medication. It does not fully predict pharmacodynamics, meaning how the medication affects the body or whether it will be clinically effective for a specific condition.
Drug-drug interactions can also change how relevant a genetic result is. A patient may genetically appear to be a normal metabolizer, but another medication may inhibit the same pathway and change how the drug is processed in practice.
Not all medications have actionable pharmacogenomic guidance. For many prescriptions, standard prescribing, careful monitoring, and follow-up remain the most appropriate approach.
Pharmacogenomic results are generally stable over a person’s lifetime, but their clinical relevance depends on the medication being considered at a particular point in time. A result that is not useful today may become relevant later if a new medication is being considered.
When Testing Adds the Most Clinical Value
Pharmacogenomic testing is not necessary for every patient or every medication. It tends to provide the most clinical value in more specific situations, including:
- Patients who have experienced significant or unusual medication side effects
- Patients with multiple medication failures, especially when medication metabolism may be relevant
- Patients taking complex medication regimens involving drugs with known pharmacogenomic associations
- Patients being considered for medications where pharmacogenomic testing is recommended or commonly used before prescribing
- Patients whose current medications may create drug-drug-gene interactions that affect safety or effectiveness
The usefulness of testing depends on which medications are being considered and whether the results are likely to change management. Testing is most valuable when guided by a physician who can interpret the findings in the context of the patient’s full medical history.
A Note on Insurance Coverage
Insurance coverage for pharmacogenomic testing varies by insurer, test type, and clinical indication. Medicare covers pharmacogenomic testing in certain clinical scenarios where results are considered actionable, and some private insurers have expanded coverage for specific drug-gene pairs supported by clinical guidelines. Coverage is not universal, and out-of-pocket costs can vary. Discussing coverage and cost with your physician’s office before testing is recommended.
Discuss Pharmacogenomic Testing With Your Physician
Pharmacogenomic testing is most useful when interpreted within the context of a patient’s medical history, current medications, treatment goals, and prior medication experiences. Genetic information can provide valuable insight in certain situations, but it is only one part of a broader clinical decision-making process.
Discussing medication history with a physician can help determine whether pharmacogenomic testing is likely to provide meaningful benefit. Patients who have experienced recurring medication side effects, difficulty finding effective treatment, unusual medication reactions, or complex medication management concerns may be more appropriate candidates for testing than individuals without these challenges.
Understanding when testing is helpful also requires careful interpretation of the results. Genetic findings do not automatically determine which medication a patient should or should not take. Instead, the information may help guide more personalized conversations about medication selection, dosing, monitoring, and long-term treatment planning.
Schedule a Consultation With TruCare Concierge
At TruCare Concierge, medication management is approached through the broader lens of personalized internal medicine care. Dr. Gabrielle Navon works closely with patients to evaluate medication effectiveness, side effects, chronic conditions, and long-term treatment goals while considering the many factors that influence medication response, including pharmacogenomic data when clinically appropriate.
For select patients, pharmacogenomic testing may provide additional insight that helps guide more individualized prescribing decisions and long-term medication planning. Longer appointments, continuity of care, and direct physician access allow for more thoughtful evaluation and follow-up when medication concerns become complex.
If you are looking for a more personalized, evidence-based approach to medication management and
preventive care in Chicago,
schedule a consultation to learn more about
membership at TruCare Concierge.
